Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short- and long-term effects on mAb-producing CHO cell lines after cryopreservation.

Biotechnology progress·2018
Same author

Probing the importance of clonality: Single cell subcloning of clonally derived CHO cell lines yields widely diverse clones differing in growth, productivity, and product quality.

Biotechnology progress·2017
Same author

A Community-Based Partnership to Successfully Implement and Maintain a Breast Health Navigation Program.

Journal of community health·2015
Same author

A method for achieving reciprocity of funding in community-based participatory research.

Progress in community health partnerships : research, education, and action·2015
Same author

Lurasidone: a review of its use in adult patients with bipolar I depression.

CNS drugs·2015
Same author

Secukinumab: first global approval.

Drugs·2015

Related Experiment Video

Updated: Jun 10, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Roflumilast: in chronic obstructive pulmonary disease.

Mark Sanford1

  • 1Adis, a Wolters Kluwer Business, Mairangi Bay, North Shore, Auckland, New Zealand. demail@adis.co.nz

Drugs
|August 7, 2010
PubMed
Summary

Roflumilast, a selective phosphodiesterase 4 inhibitor, offers a novel treatment for severe chronic obstructive pulmonary disease (COPD). Clinical trials show it improves lung function and reduces exacerbations in COPD patients.

Area of Science:

  • Pulmonary Medicine
  • Pharmacology

Background:

  • Chronic obstructive pulmonary disease (COPD) is a major cause of respiratory morbidity and mortality.
  • Current treatments for COPD primarily focus on symptom management and exacerbation prevention.

Purpose of the Study:

  • To evaluate the efficacy and safety of roflumilast, a selective phosphodiesterase 4 inhibitor, as a novel treatment for patients with severe COPD.
  • To assess the impact of roflumilast on lung function (FEV(1)) and COPD exacerbation rates.

Main Methods:

  • Four randomized, double-blind, multinational trials were conducted in patients with moderate to severe or severe COPD.
  • Roflumilast 500 microg/day was compared with placebo, both as monotherapy and in combination with long-acting bronchodilators (salmeterol, tiotropium bromide).
  • Primary endpoints included changes in pre- and post-bronchodilator FEV(1) and COPD exacerbation rates.

More Related Videos

Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
04:59

Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia

Published on: May 30, 2025

Related Experiment Videos

Last Updated: Jun 10, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
04:59

Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia

Published on: May 30, 2025

Main Results:

  • Roflumilast 500 microg/day demonstrated significantly greater improvements in FEV(1) compared to placebo across four trials.
  • In three of four trials, roflumilast significantly reduced the COPD exacerbation rate, with a pooled analysis showing a 17% reduction over placebo.
  • Combination therapy with roflumilast and long-acting bronchodilators resulted in greater FEV(1) increases than placebo plus long-acting bronchodilators.
  • Roflumilast exhibited an acceptable tolerability profile, with similar rates of serious adverse events and medication discontinuation due to adverse events compared to placebo.

Conclusions:

  • Roflumilast is an effective oral treatment for severe COPD, improving lung function and reducing exacerbations.
  • The addition of roflumilast to long-acting bronchodilators further enhances lung function benefits.
  • Roflumilast presents a viable therapeutic option with an acceptable safety profile for managing severe COPD.